Tin tức & Cập nhật

Ipilimumab plus nivolumab elicits response in mCRPC
Ipilimumab plus nivolumab elicits response in mCRPC
02 Jan 2025 bởiStephen Padilla

Use of dual immune checkpoint inhibitors (ICIs), nivolumab and ipilimumab, exhibits responses in some molecularly selected patients with metastatic castration-resistant prostate cancer (mCRPC), including those with mismatch repair deficiency (dMMR), nonsynonymous tumour mutational burden ≥7.1 muts/Mb (hTMB), a BRCA2 mutation (BRCAm), or biallelic CDK12 inactivation (CDK12i).

Ipilimumab plus nivolumab elicits response in mCRPC
02 Jan 2025
Salbutamol may lower risk, improve prognosis of prostate cancer
Salbutamol may lower risk, improve prognosis of prostate cancer
14 Dec 2024

The incidence of prostate cancer is reduced among individuals treated with salbutamol, a short-acting beta-2 adrenergic agonist, according to a study.

Salbutamol may lower risk, improve prognosis of prostate cancer
14 Dec 2024
Topical estriol gel prevents UTI, improves vaginal health in postmenopausal women
Topical estriol gel prevents UTI, improves vaginal health in postmenopausal women
15 Nov 2024